Harvard Bioscience (HBIO) Total Non-Current Liabilities (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Total Non-Current Liabilities data on file, last reported at $66.7 million in Q1 2026.

• Total Non-Current Liabilities for Q1 2026 came in at $66.7 million, up 5.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $66.7 million (up 5.03% YoY), and the FY2025 annual result was $65.0 million, up 4.8% from the prior year.
• Total Non-Current Liabilities rose to $66.7 million in Q1 2026 per HBIO's latest filing, from $65.0 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $81.1 million in Q1 2022 and troughed at $60.1 million in Q2 2024.
• A 5-year average of $67.0 million and a median of $64.6 million in 2023 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities advanced 13.73% in 2022, then retreated 14.07% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $72.1 million in 2022, then slipped by 12.92% to $62.8 million in 2023, then retreated by 1.22% to $62.0 million in 2024, then rose by 4.8% to $65.0 million in 2025, then rose by 2.64% to $66.7 million in 2026.
• Business Quant data shows HBIO's Total Non-Current Liabilities at $66.7 million in Q1 2026, $65.0 million in Q4 2025, and $62.5 million in Q3 2025.